EGFR inhibitor compounds
Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
2. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 , wherein the compound is
4. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 , wherein the compound is
6. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6 , wherein the compound is
8. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 8 , wherein the compound is
10. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 10 , wherein the compound is
12. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 12 , wherein the compound is